Data completeness
0/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALRELEASE is an oral extended-release capsule small molecule in pre-launch development by Roche. The mechanism of action, pharmacologic class, and therapeutic indications are not yet publicly disclosed. This product represents a novel formulation approach designed to optimize patient convenience and dosing frequency.
Pre-Launch
As a pre-launch asset from Roche, this product will require significant commercial infrastructure build-out; career opportunities will focus on launch preparation and early market establishment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VALRELEASE offers early-career entry points in a Roche pre-launch program with potential for high visibility if regulatory approval is achieved. Team size and scope remain undefined until product designation and indication clarity are announced.
Brand ManagerMedical Science Liaison
Worked on VALRELEASE at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.